Mannkind Corp

NASDAQ: MNKD
$4.12
-$0.03 (-0.7%)
Closing price April 15, 2024
MannKind Corporation is a pioneering biopharmaceutical firm dedicated to creating inhaled therapeutic products for diabetes and rare lung diseases. Its flagship product, Afrezza, is an innovative inhaled insulin offering a new approach to glycemic control in adults. Additionally, MannKind is developing treatments for pulmonary arterial hypertension and other serious lung conditions. With strategic partnerships for global distribution and a commitment to advancing respiratory health, MannKind stands at the forefront of inhalation technology for medical treatments.
The December 31 short interest data has been compared with the previous report, and short interest in these selected biotech stocks increased.
The December 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
The November 29 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The November 15 short interest data has been compared with the previous report, and short interest in...
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The October 31 short interest data has been compared with the previous report, and short interest in...
The October 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The September 30 short interest data has been compared with the previous report, and short interest in...
The September 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The August 30 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The August 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Short sellers seem to have many emerging and speculative biotech stocks targeted for termination. Here are eight of them against which short sellers are betting the farm.
The July 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
The July 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The June 28 short interest data has been compared with the previous report, and short interest in most...
The June 14 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.